Research presented at the European Respiratory Society (ERS) Congress in Amsterdam has shown that biologic treatments may help reduce the need for non-invasive ventilation (NIV) among patients with chronic obstructive pulmonary disease (COPD) and type II inflammation. The study was highlighted by Healio and led by Truong-An (Andrew) Ho, MD, a Pulmonary and Critical Care Fellow at the Temple Lung Center.
According to the findings, patients who received biologics experienced a significant reduction in NIV utilization. There was also an observed trend toward fewer intensive care unit admissions. “The findings suggest that biologics may reduce the burden of the most severe exacerbations,” Dr. Ho stated during his presentation.
This research provides new insights into managing severe cases of COPD with type II inflammation and points to potential benefits from using biologic therapies in real-world settings.
